Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine

被引：11
作者：
Winokur, Patricia L. [1 ,2 ]
Patel, Shital M. [3 ,4 ]
Brady, Rebecca [5 ]
Chen, Wilbur H. [6 ]
El-Kamary, Samer S. [6 ]
Edwards, Kathryn [8 ]
Creech, C. Buddy [8 ]
Frey, Sharon
Keitel, Wendy A. [4 ]
Belshe, Robert [9 ]
Walter, Emmanuel [10 ]
Bellamy, Abbie [7 ]
Hill, Heather [7 ]
机构：
[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[2] Iowa City VA Healthcare Syst, Iowa City, IA USA
[3] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[4] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA
[5] Cincinnati Childrens Hosp, Gamble Program Clin Studies, Cincinnati, OH USA
[6] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA
[7] EMMES Corp, Rockville, MD USA
[8] Vanderbilt Univ, Dept Pediat, Nashville, TN 37235 USA
[9] St Louis Univ, Dept Internal Med, St Louis, MO 63103 USA
[10] Duke Univ, Sch Med, Dept Pediat, Durham, NC USA
来源：
JOURNAL OF INFECTIOUS DISEASES | 2015年 / 212卷 / 04期
基金：
美国国家卫生研究院;
关键词：
H5N1; influenza; vaccine; prime-boost; MEMORY B-CELLS; PANDEMIC INFLUENZA; ANTIGENIC VARIANT; HUMANS;
D O I：
10.1093/infdis/jiv087
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Influenza A(H5N1) vaccination strategies that improve the speed of the immunological response and cross-clade protection are desired. We compared the immunogenicity of a single 15-mu g or 90-mu g dose of A/H5N1/Indonesia/05/05 (clade 2) vaccine in adults who were previously primed with A/H5N1/Vietnam/1203/2004 (clade 1) vaccine. High-dose vaccine resulted in significantly higher titers to both clade 1 and 2 antigens. Clade 2 titers were unaffected by the previous dose of clade 1 vaccine. Low-dose priming with a mismatched pandemic influenza A(H5N1) vaccine would improve the rapidity, magnitude, and cross-reactivity of the immunological response following a single high-dose, unadjuvanted, pandemic vaccine.
引用
收藏
页码：525 / 530
页数：6
相关论文
共 50 条
  • [1] Safety and Immunogenicity of a Prepandemic Influenza A (H5N1) Vaccine in Children
    Vajo, Zoltan
    Kosa, Lajos
    Szilvasy, Istvan
    Pauliny, Zsuzsanna
    Bartha, Kalman
    Visontay, Ildiko
    Kis, Agnes
    Tarjan, Ildiko
    Rozsa, Noemi
    Jankovics, Istvan
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (12) : 1052 - 1056
  • [2] Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans
    Zangwill, Kenneth M.
    Treanor, John J.
    Campbell, James D.
    Noah, Diana L.
    Ryea, Jennifer
    JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (04) : 580 - 583
  • [3] Characterization of a whole, inactivated influenza (H5N1) vaccine
    Tada, Yoshikazu
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2008, 2 (06) : 261 - 266
  • [4] Clinical vaccine development for H5N1 influenza
    Clegg, Christopher H.
    Rininger, Joseph A.
    Baldwin, Susan L.
    EXPERT REVIEW OF VACCINES, 2013, 12 (07) : 767 - 777
  • [5] Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains
    Hoschler, Katja
    Gopal, Robin
    Andrews, Nick
    Saville, Melanie
    Pepin, Stephanie
    Wood, John
    Zambon, Maria C.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2007, 1 (5-6) : 199 - 206
  • [6] An Inactivated, Adjuvanted Whole Virion Clade 2.2 H5N1 (A/Chicken/Astana/6/05) Influenza Vaccine Is Safe and Immunogenic in a Single Dose in Humans
    Sansyzbay, Abylay R.
    Erofeeva, Marianna K.
    Khairullin, Berik M.
    Sandybayev, Nurlan T.
    Kydyrbayev, Zhailaubay K.
    Mamadaliyev, Seidigapbar M.
    Kassenov, Markhabat M.
    Sergeeva, Maria V.
    Romanova, Julia R.
    Krivitskaya, Vera Z.
    Kiselev, Oleg I.
    Stukova, Marina A.
    CLINICAL AND VACCINE IMMUNOLOGY, 2013, 20 (08) : 1314 - 1319
  • [7] Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial
    Keitel, Wendy
    Groth, Nicola
    Lattanzi, Maria
    Praus, Michaela
    Hilbert, Anne Katrin
    Borkowski, Astrid
    Tsai, Ted F.
    VACCINE, 2010, 28 (03) : 840 - 848
  • [8] Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies
    Feldstein, Leora R.
    Matrajt, Laura
    Halloran, M. Elizabeth
    Keitel, Wendy A.
    Longini, Ira M., Jr.
    VACCINE, 2016, 34 (33) : 3796 - 3802
  • [9] The safety and immunogenicity of a MF59- adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: An observational study
    Wei S.-H.
    Liu M.-T.
    Tsai Y.-C.
    Liao C.-H.
    Chen C.-M.
    Wang W.-Y.
    Huang Y.-L.
    Chang F.-Y.
    Chou P.
    BMC Infectious Diseases, 14 (1)
  • [10] The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study
    Wei, Sung-Hsi
    Liu, Ming-Tsan
    Tsai, Yao-Chou
    Liao, Chung-Hsin
    Chen, Chih-Ming
    Wang, Wei-Yao
    Huang, Yi-Lung
    Chang, Feng-Yee
    Chou, Pesus
    BMC INFECTIOUS DISEASES, 2014, 14
12345